304 related articles for article (PubMed ID: 9439759)
21. Eye muscle antibodies in patients with ocular myasthenia gravis: possible mechanism for eye muscle inflammation in acetylcholine-receptor antibody-negative patients.
Gunji K; Skolnick C; Bednarczuk T; Benes S; Ackrell BA; Cochran B; Kennerdell JS; Wall JR
Clin Immunol Immunopathol; 1998 Jun; 87(3):276-81. PubMed ID: 9646837
[TBL] [Abstract][Full Text] [Related]
22. Experimental autoimmune myasthenia gravis.
Lindstrom J
J Neurol Neurosurg Psychiatry; 1980 Jul; 43(7):568-76. PubMed ID: 6249892
[TBL] [Abstract][Full Text] [Related]
23. Refractoriness to a second episode of experimental myasthenia gravis. Correlation with AChR concentration and morphologic appearance of the postsynaptic membrane.
Corey AL; Richman DP; Agius MA; Wollmann RL
J Immunol; 1987 May; 138(10):3269-75. PubMed ID: 3494763
[TBL] [Abstract][Full Text] [Related]
24. Animal models of myasthenia gravis.
Christadoss P; Poussin M; Deng C
Clin Immunol; 2000 Feb; 94(2):75-87. PubMed ID: 10637092
[TBL] [Abstract][Full Text] [Related]
25. Modulation of anti-acetylcholine receptor antibody specificities and of experimental autoimmune myasthenia gravis by synthetic peptides.
Souroujon MC; Carmon S; Fuchs S
Immunol Lett; 1992 Sep; 34(1):19-25. PubMed ID: 1282497
[TBL] [Abstract][Full Text] [Related]
26. Cellular immune response to acetylcholine receptors in murine experimental autoimmune myasthenia gravis: inhibition with monoclonal anti-I-A antibodies.
Christadoss P; Lindstrom J; Talal N
Cell Immunol; 1983 Oct; 81(1):1-8. PubMed ID: 6577968
[TBL] [Abstract][Full Text] [Related]
27. B cell autoimmunity to acetylcholine receptor and its subunits in Lewis rats over the course of experimental autoimmune myasthenia gravis.
Wang ZY; Link H; Qiao J; Olsson T; Huang WX
J Neuroimmunol; 1993 Jun; 45(1-2):103-12. PubMed ID: 8331155
[TBL] [Abstract][Full Text] [Related]
28. Immune regulation of experimental myasthenia.
Fuchs S; Bartfeld D; Eshhar Z; Feingold C; Mochly-Rosen D; Novick D; Schwartz M; Tarrab-Hazdai R
J Neurol Neurosurg Psychiatry; 1980 Jul; 43(7):634-43. PubMed ID: 7400824
[TBL] [Abstract][Full Text] [Related]
29. Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology.
Fichtner ML; Jiang R; Bourke A; Nowak RJ; O'Connor KC
Front Immunol; 2020; 11():776. PubMed ID: 32547535
[TBL] [Abstract][Full Text] [Related]
30. Spectrotypic analysis of antibodies to acetylcholine receptors in experimental autoimmune myasthenia gravis.
Bionda A; De Baets MH; Tzartos SJ; Lindstrom JM; Weigle WO; Theophilopoulos AN
Clin Exp Immunol; 1984 Jul; 57(1):41-50. PubMed ID: 6611231
[TBL] [Abstract][Full Text] [Related]
31. C5 gene influences the development of murine myasthenia gravis.
Christadoss P
J Immunol; 1988 Apr; 140(8):2589-92. PubMed ID: 3356901
[TBL] [Abstract][Full Text] [Related]
32. Factors in the production of experimental autoimmune myasthenia gravis in acetylcholine receptor immunized rabbits.
Niemi WD; Nastuk WL; Chang HW; Plescia OJ; Plescia AM
Ann N Y Acad Sci; 1981; 377():222-36. PubMed ID: 6951475
[TBL] [Abstract][Full Text] [Related]
33. Autoimmune diseases against cell surface receptors: myasthenia gravis, a prototype anti-receptor disease.
De Baets MH
Neth J Med; 1994 Dec; 45(6):294-301. PubMed ID: 7838246
[TBL] [Abstract][Full Text] [Related]
34. [Acetylcholine receptor antibody titer, sensitivity to curare electromyogram and disease severity in myasthenia gravis].
Chen SM
Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1991 Jun; 24(3):169-73, 189. PubMed ID: 1889330
[TBL] [Abstract][Full Text] [Related]
35. Prevention of experimental autoimmune myasthenia gravis by manipulation of the immune network with a complementary peptide for the acetylcholine receptor.
Araga S; LeBoeuf RD; Blalock JE
Proc Natl Acad Sci U S A; 1993 Sep; 90(18):8747-51. PubMed ID: 8378359
[TBL] [Abstract][Full Text] [Related]
36. On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope.
Atassi MZ; Oshima M; Deitiker P
Crit Rev Immunol; 2001; 21(1-3):1-27. PubMed ID: 11642597
[TBL] [Abstract][Full Text] [Related]
37. Passively transferred experimental autoimmune myasthenia gravis. Sequential and quantitative study of the motor end-plate fine structure and ultrastructural localization of immune complexes (IgG and C3), and of the acetylcholine receptor.
Engel AG; Sakakibara H; Sahashi K; Lindstrom JM; Lambert EH; Lennon VA
Neurology; 1979 Feb; 29(2):179-88. PubMed ID: 571062
[TBL] [Abstract][Full Text] [Related]
38. Induction of experimental autoimmune myasthenia gravis with acetylcholine receptors using a nonionic block copolymer as adjuvant.
Shenoy M; Christadoss P
Immunol Invest; 1993 Jun; 22(4):267-82. PubMed ID: 8359864
[TBL] [Abstract][Full Text] [Related]
39. B cell responses to acetylcholine receptor in rats orally tolerized against experimental autoimmune myasthenia gravis.
Wang ZY; Huang J; Olsson T; He B; Link H
J Neurol Sci; 1995 Feb; 128(2):167-74. PubMed ID: 7537794
[TBL] [Abstract][Full Text] [Related]
40. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.
Cole RN; Reddel SW; Gervásio OL; Phillips WD
Ann Neurol; 2008 Jun; 63(6):782-9. PubMed ID: 18384168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
